Texture Features and PDL1 in CT-PET 18 FDG

Non Small Cell Lung Cancer Clinical Trial

Official title:

Correlation Between Texture Features With CT-PET 18 FDG and Overexpression of PDL1 in Non-small-cell Lung Carcinomas During the Initial Staging.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04309422
• Other study ID #: RECHMPL19_0623
• Status: Completed
• Start date: April 1, 2018
• Est. completion date: January 31, 2020

Study information

• Verified date: March 2020
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Search correlation between texture features in CT-PET 18 FDG and overexpression of PDL1 in non-small cell lung carcinomas during the inital staging.

The hypothesis is that overexpression of PDL1is correlated with at least one texture feature among those selected.

84 CT-PET 18 FDG at the initial staging of a non small cell lung carcinoma (adenocarcinoma or squamous cell carcinoma), whose the biopsed site was the primitive site or the drainage lymphadenopathy, without previous treatment, were recruited and analyzed by a software allowing to estimate texture features.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: January 31, 2020
• Est. primary completion date: October 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• adult patient ;

• first CT-PET 18 FDG realized for the inital staging ;

• absence of previous treatment for a thoracic neoplasm ;

• biopsy realized on the primitive site or local drainage lymphadenopathy ;

• primitive site viewable with morphological imagery ;

• availability of evaluation of PDL1's overexpression ;

Exclusion criteria

• Refusal to participate in this research

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Non Small Cell Lung Cancer

Locations

Country	Name	City	State
France	Uh Montpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between at least one texture feature and overexpression of PDL1	Correlation between at least one texture feature and overexpression of PDL1	1 day